Reformulary Group, Canada’s leading, independent drug plan management company, today announced it has signed Leamington, Ontario-based cannabis producer Aphria Inc. as its second Licensed Producer of medical cannabis for employer plans.
The agreement will provide subscribers of the Reformulary Cannabis Standard™ – the first cannabis formulary in Canada – with preferred pricing options for cannabis that is 100 per cent greenhouse grown. The partnership will help Canadian employers navigate the process of covering medical cannabis in their benefit plans and support the development of a database that captures real-world patient-reported data.
“Aphria has built a reputation as a leading low cost producer of high-quality medical cannabis to Canadians, including Canadian Veterans,” said Helen Stevenson, Reformulary Group founder and CEO. “This partnership will ensure employers that choose to cover cannabis have expert guidance on how to include cannabis in their benefit plans, and have access to specific Aphria products.”
“We’re proud to partner with Reformulary to support employers choosing to add cannabis coverage to their benefit plans, and to support their eligible employees,” said Sarah Dobbin, Director of Medical at Aphria. “It’s critical for employers to have the necessary resources to effectively offer coverage, but also to enable them to provide their employees with access to high-quality, clean and safe cannabis products.”
This agreement comes on the heels of a series of announcements from Reformulary Group, first that it had created the Cannabis Formulary Committee, an expert group designed to review the best available evidence for the use of medical cannabis and that it signed its first Licensed Producer.
